Sulfinpyrazone

Summary

Sulfinpyrazone (CHEMBL832) is an approved small-molecule uricosuric drug (ATC M04AB02) targeting SLC22A12 and FPR1; indicated across 1 condition including gout.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M04AB02
• Targets: 2 (SLC22A12, FPR1)
• Indications: 1 condition
• Chemistry: C23H20N2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL832
Name	Sulfinpyrazone
Type	Small molecule
Max phase	4
ChEBI	CHEBI:9342
ATC	M04AB02
Molecular formula	C23H20N2O3S
InChIKey	MBGGBVCUIVRRBF-UHFFFAOYSA-N

SMILES: O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1

Pharmacological roles (ChEBI): uricosuric drug.

Also known as: Anturan, Anturane, NSC-75925, Sulfinpirazona, Sulfinpyrazone, sulfinpyrazone, SID11112139, SID26747070, SID855982, SULFINPYRAZONE, Suphinpyrazone, SID124881954

Patent coverage: 3,603 distinct patent families (13,780 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC22A12	Urate anion exchanger 1	Inhibition	4	0%	Q96S37
FPR1	FPR1	Antagonist	5	0%	P21462

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Menin/Histone-lysine N-methyltransferase MLL, fMet-Leu-Phe receptor, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 36 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NAPRT	9.3	Ki	0.5	nM	CHEMBL_ACT_19323245
Q9F4F7	8.96	Potency	1.1	nM	CHEMBL_ACT_4805377
ALDH1A1	6.1	Potency	794.3	nM	CHEMBL_ACT_4167918
TDP1	5.95	Potency	1122	nM	CHEMBL_ACT_3930158
MEN1	5.6	Potency	2512	nM	CHEMBL_ACT_4553760
HSD17B10	5.3	Potency	5012	nM	CHEMBL_ACT_4873607
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_4997965
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_5063015
CYP3A4	5.2	AC50	6310	nM	CHEMBL_ACT_6057579
KDM4E	5	Potency	10000	nM	CHEMBL_ACT_3741524
HPGD	5	Potency	10000	nM	CHEMBL_ACT_4776203
CYP2C9	5	Potency	10000	nM	CHEMBL_ACT_5033428
CYP2C9	5	AC50	10000	nM	CHEMBL_ACT_6049866
FPR1	5	IC50	10000	nM	CHEMBL_ACT_6182024

Target pathways

Aggregated over 2 target gene(s): SLC22A12, FPR1.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
Disease	1	SLC22A12
Transport of small molecules	1	SLC22A12
G alpha (i) signalling events	1	FPR1
R-HSA-425366	1	SLC22A12
SLC-mediated transmembrane transport	1	SLC22A12
Formyl peptide receptors bind formyl peptides and many other ligands	1	FPR1
R-HSA-549132	1	SLC22A12
Organic anion transport by SLC22 transporters	1	SLC22A12
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1)	1	SLC22A12
SLC transporter disorders	1	SLC22A12
Disorders of transmembrane transporters	1	SLC22A12
Interleukin-10 signaling	1	FPR1
Neutrophil degranulation	1	FPR1

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	1
response to xenobiotic stimulus	1
obsolete organic anion transport	1
urate transport	1
cellular homeostasis	1
cellular response to insulin stimulus	1
urate metabolic process	1
renal urate salt excretion	1
transmembrane transport	1
complement receptor mediated signaling pathway	1
chemotaxis	1
inflammatory response	1
signal transduction	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gout	4	MONDO:0005393	EFO:0004274

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

25 molecules share ≥1 primary target. Top 25 by shared-target count:

Molecule	Source	Status	Shared targets
PROBENECID	ChEMBL + PubChem	Phase 4 (approved)	SLC22A12
APREPITANT	ChEMBL	Phase 4 (approved)	FPR1
BENZARONE	ChEMBL	Phase 4 (approved)	SLC22A12
BENZBROMARONE	ChEMBL	Phase 4 (approved)	SLC22A12
CINACALCET	ChEMBL	Phase 4 (approved)	FPR1
FENOFIBRIC ACID	ChEMBL	Phase 4 (approved)	SLC22A12
LESINURAD	ChEMBL	Phase 4 (approved)	SLC22A12
LOPERAMIDE	ChEMBL	Phase 4 (approved)	FPR1
MONTELUKAST	ChEMBL	Phase 4 (approved)	FPR1
PENICILLIN G	ChEMBL	Phase 4 (approved)	FPR1
PERPHENAZINE	ChEMBL	Phase 4 (approved)	FPR1
PHENYLBUTAZONE	ChEMBL	Phase 4 (approved)	FPR1
DOTINURAD	ChEMBL	Phase 3	SLC22A12
SHR-4640	ChEMBL	Phase 3	SLC22A12
ARHALOFENATE	ChEMBL	Phase 2	SLC22A12
FORETINIB	ChEMBL	Phase 2	FPR1
NIGULDIPINE	ChEMBL	Phase 2	FPR1
PF-05089771	ChEMBL	Phase 2	SLC22A12
PULIGINURAD	ChEMBL	Phase 2	SLC22A12
VERINURAD	ChEMBL	Phase 2	SLC22A12
Belzutifan	PubChem	Approved	FPR1
chenodiol	PubChem	Approved	FPR1
cyclosporine	PubChem	Approved	FPR1
Deoxycholic Acid	PubChem	Approved	FPR1
Febuxostat	PubChem	Approved	SLC22A12